Summary

Hester Biosciences has announced its unaudited financial results for Q3 and 9M FY26. The Poultry Healthcare Division showed a significant growth, while the Animal Healthcare Division faced a decline due to delays in government-led immunisation programmes. The company received a regulatory milestone with the marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine.

Key Highlights

1. 1

   Standalone Q3 Revenue up 12%

2. 2

   Standalone Profit up 140%

3. 3

   9M Standalone Revenue down 5%

4. 4

   9M Standalone Profit up 16%

5. 5

   Consolidated Q3 Revenue up 22%

6. 6

   Consolidated Q3 Profit down 18%

7. 7

   9M Consolidated Revenue up 1%

8. 8

   9M Consolidated Profit up 50%

9. 9

   Poultry Healthcare Division grew by 32% in Q3 FY26

10. 10

    Animal Healthcare Division declined by 38% in Q3 FY26

11. 11

    H9N2 Avian Influenza vaccine received marketing and manufacturing licenses